alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.1750 External programmable pacemaker pulse generator. ( a ) *Identification.* An external programmable pacemaker pulse generators is a device that can be programmed to produce one or more pulses at preselected intervals; this device is used in electrophysiological studies.
( b ) *Classification.* Class II (performance standards).
#### § 1.1403-1 Cross references.

For provisions relating to the requirement for filing returns with respect to net earnings from self-employment, see § 1.6017-1. For provisions relating to declarations of estimated tax on self-employment income, see §§ 1.6015(a) to 1.6015(j)-1, inclusive. For other administrative provisions relating to the tax on self-employment income, see the applicable sections of the regulations in this part (§ 1.6001-1 *et seq.*) and the applicable sections of the regulations in part 301 of this chapter (Regulations on Procedure and Administration).

[T.D. 7427, 41 FR 34026, Aug. 12, 1976]
§ 876.5862 Hemodialyzer with expanded solute removal profile. ( a ) *Identification.* A hemodialyzer with expanded solute removal profile is a device intended for use a part of an artificial kidney system for the treatment of patients with renal failure by performing such therapies as hemodialysis, hemofiltration, and hemodiafiltration. A hemodialyzer with expanded solute removal profile includes modifications to the semipermeable membrane that allows for increased removal of uremic retention solutes compared with standard high-flux hemodialyzers of the high permeability hemodialysis system classification (§ 876.5860), including solutes at the upper end of the “middle” molecular weight range (0.5 kDa to 60 kDa). This device is intended to be used with the extracorporeal hemodialysis delivery systems, blood tubing sets, blood access devices, and accessories regulated under §§ 876.5820, 876.5860, 876.5540, and/or 876.5600.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) Clinical performance testing under anticipated conditions of use must evaluate the solute removal profile and document all adverse events.
( 2 ) Non-clinical performance testing data must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested: ( i ) Ultrafiltration;
( ii ) Blood and dialysate pressure drop;
( iii ) Clearance rates;
( iv ) Sieving coefficients;
( v ) Mechanical hemolysis;
( vi ) Structural integrity;
( vii ) Blood compartment integrity;
( viii ) Volume of the blood compartment; and
( ix ) Endotoxin retention of the dialyzer membrane.
( 3 ) The tissue-contacting components of the device must be demonstrated to be biocompatible. Biocompatibility evaluation must include a chemical analysis of the dialyzer membrane.
( 4 ) Performance data must demonstrate the sterility of the patient-contacting components of the device.
( 5 ) The patient-contacting components of the device must be demonstrated to be non-pyrogenic.
( 6 ) Performance data must support the shelf life of the device by demonstrating continued sterility, package integrity, and device functionality over the identified shelf life.
( 7 ) Device labeling must include: ( i ) Shelf life;
( ii ) Storage conditions;
( iii ) Instructions for the preparation of the hemodialyzer, initiation of dialysis, troubleshooting, and discontinuance of dialysis;
( iv ) Membrane surface area, priming (blood) volume, maximum transmembrane pressure, maximum blood flow and maximum dialysate rate for each model;
( v ) A non-pyrogenic statement;
( vi ) A summary of the in vitro performance data, provided in tabular form; and
( vii ) A summary of the clinical performance data.
[89 FR 72716, Sept. 6, 2024]
|   |  1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|--------|----------|--------------------------------------------------------------------------------------------------------------------------------------|

|   |  2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. |
|--------|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Date:  |  May 17, 2010 |   | By:    |  /s/ Julie Smolyansky                                                           |   |
|--------|--------------------|--------|--------|--------------------------------------------------------------------------------------|--------|
|   |               |   |   |  Julie Smolyanky Chief Executive Officer, President and Director |   |

----
<Page>

EXHIBIT 32


                    CERTIFICATION OF CHIEF EXECUTIVE OFFICER
                       AND ACTING CHIEF FINANCIAL OFFICER
                       PURSUANT TO 18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


      In connection with the quarterly report on Form 10-Q of EMRISE Corporation
(the "Company") for the period ended June 30, 2006 (the "Report"), the
undersigned hereby certify in their capacities as Chief Executive Officer and
Chief Financial Officer of the Company, respectively, pursuant to 18 U.S.C.
section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that:

      1.    the Report fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934, as amended; and

      2.    the information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the
Company.

Dated: January 17, 2007                 By: /s/ Carmine T. Oliva
                                            ------------------------------------
                                            Carmine T. Oliva
                                            Chief Executive Officer
                                            (principal executive officer)


Dated: January 17, 2007                 By: /s/ Carmine T. Oliva
                                            ------------------------------------
                                            Carmine T. Oliva
                                            Acting Chief Financial Officer
                                            (principal financial officer)

      A signed original of this written statement required by Section 906, or
other document authenticating, acknowledging, or otherwise adopting the
signatures that appear in typed form within the electronic version of this
written statement required by Section 906, has been provided to the Company and
will be retained by the Company and furnished to the Securities and Exchange
Commission or its staff upon request.
§ 876.5130 Urological catheter and accessories. ( a ) *Identification.* A urological catheter and accessories is a flexible tubular device that is inserted through the urethra and used to pass fluids to or from the urinary tract. This generic type of device includes radiopaque urological catheters, ureteral catheters, urethral catheters, coudé catheters, balloon retention type catheters, straight catheters, upper urinary tract catheters, double lumen female urethrographic catheters, disposable ureteral catheters, male urethrographic catheters, and urological catheter accessories including ureteral catheter stylets, ureteral catheter adapters, ureteral catheter holders, ureteral catheter stylets, ureteral catheterization trays, and the gastro-urological irrigation tray (for urological use).
( b ) *Classification.* ( 1 ) Class II (performance standards).
( 2 ) Class I for the ureteral stylet (guidewire), stylet for gastrourological catheter, ureteral catheter adapter, ureteral catheter connector, and ureteral catheter holder. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.
[48 FR 53023, Nov. 23, 1983, as amended at 61 FR 1122, Jan. 16, 1996; 66 FR 38801, July 25, 2001]
# C_2016156EN.01001301.xml

| 2.5.2016 | EN | Official Journal of the European Union | C 156/13 |
| --- | --- | --- | --- |

2.5.2016

EN

Official Journal of the European Union

C 156/13

---

Judgment of the Court (Sixth Chamber) of 10 March 2016 — European Commission v Kingdom of Spain

(Case C-38/15) (1)

1

((Failure of a Member State to fulfil obligations - Directive 91/271/EEC - Urban waste water treatment - Collection and treatment systems - Discharges in sensitive areas - Monitoring methods - Collecting of samples))

(2016/C 156/17)

Language of the case: Spanish

Parties

Parties

Applicant: European Commission (represented by: E. Sanfrutos Cano, E. Manhaeve and D. Loma-Osorio Lerena, acting as Agents)

Applicant:

Defendant: Kingdom of Spain (represented by: A. Gavela Llopis, acting as Agent)

Defendant:

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Declares that by, failing to provide adequately for the treatment of urban waste water discharged in sensitive areas and deriving from certain agglomerations, the Kingdom of Spain has failed to fulfil its obligations under, first, Article 4 of Council Directive 91/271/EEC of 21 May 1991 concerning urban waste water treatment, as amended by Regulation (EC) No 1137/2008 of the European Parliament and of the Council of 22 October 2008, in relation to the agglomeration of Pontevedra-Marín-Poio-Bueu and, second, Article 5(2) and (3) of that directive, in relation to the agglomerations of Berga, Figueres, El Terri (Banyoles) and Pontevedra-Marín-Poio-Bueu; |
| --- | --- |

1.

Declares that by, failing to provide adequately for the treatment of urban waste water discharged in sensitive areas and deriving from certain agglomerations, the Kingdom of Spain has failed to fulfil its obligations under, first, Article 4 of Council Directive 91/271/EEC of 21 May 1991 concerning urban waste water treatment, as amended by Regulation (EC) No 1137/2008 of the European Parliament and of the Council of 22 October 2008, in relation to the agglomeration of Pontevedra-Marín-Poio-Bueu and, second, Article 5(2) and (3) of that directive, in relation to the agglomerations of Berga, Figueres, El Terri (Banyoles) and Pontevedra-Marín-Poio-Bueu;

| 2. | Dismisses the remainder of the action; |
| --- | --- |

2.

Dismisses the remainder of the action;

| 3. | Orders the European Commission and the Kingdom of Spain to bear their own respective costs. |
| --- | --- |

3.

Orders the European Commission and the Kingdom of Spain to bear their own respective costs.

---

(1)  OJ C 127, 20.4.2015.

1

---
§ 1.117-4 Items not considered as scholarships or fellowship grants. The following payments or allowances shall not be considered to be amounts received as a scholarship or a fellowship grant for the purpose of section 117: ( a ) *Educational and training allowances to veterans.* Educational and training allowances to a veteran pursuant to section 400 of the Servicemen's Readjustment Act of 1944 (58 Stat. 287) or pursuant to 38 U.S.C. 1631 (formerly section 231 of the Veterans' Readjustment Assistance Act of 1952).
( b ) *Allowances to members of the Armed Forces of the United States.* Tuition and subsistence allowances to members of the Armed Forces of the United States who are students at an educational institution operated by the United States or approved by the United States for their education and training, such as the United States Naval Academy and the United States Military Academy.
( c ) *Amounts paid as compensation for services or primarily for the benefit of the grantor.* ( 1 ) Except as provided in paragraph (a) of §§ 1.117-2 and 1.117-5, any amount paid or allowed to, or on behalf of, an individual to enable him to pursue studies or research, if such amount represents either compensation for past, present, or future employment services or represents payment for services which are subject to the direction or supervision of the grantor.
( 2 ) Any amount paid or allowed to, or on behalf of, an individual to enable him to pursue studies or research primarily for the benefit of the grantor.
However, amounts paid or allowed to, or on behalf of, an individual to enable him to pursue studies or research are considered to be amounts received as a scholarship or fellowship grant for the purpose of section 117 if the primary purpose of the studies or research is to further the education and training of the recipient in his individual capacity and the amount provided by the grantor for such purpose does not represent compensation or payment for the services described in subparagraph (1) of this paragraph. Neither the fact that the recipient is required to furnish reports of his progress to the grantor, nor the fact that the results of his studies or research may be of some incidental benefits to the grantor shall, of itself, be considered to destroy the essential character of such amount as a scholarship or fellowship grant. [T.D. 6500, 25 FR 11402, Nov. 26, 1960; 25 FR 14021, Dec. 21, 1960, as amended by T.D. 8032, 50 FR 27232, July 2, 1985]
W.S. Dodge Oil Co, Inc. 

3710 Fruitland Avenue 

Maywood, California 90270 

(323) 583-3478 • www.wsdodgeoil.com • FAX (323) 583-0950 

August 27, 2013 

Mr. Stan Cowen, Air Quality Engineer 

Ventura County Air Pollution Control District 

669 County Square Drive 

Ventura, CA 93003 

Re: Rule 74.31-Metalworking Fluids and Direct Contact Lubricants 

Dear Mr. Cowen: 

The W.S. Dodge Company ("Dodge") is pleased to fully endorse the adoption of Rule 74.31-Metalworking Fluids and 

Direct Contact Lubricants. 

Dodge is the largest provider of metalworking fluids in the Greater Southern California area, including Ventura County. 

We are in our 52nd year of family owned operation. Our offerings run the full range of cutting, grinding, forming, forging, 

heat treating, and rust protecting fluids. 

Dodge also worked tirelessly with the South Coast Air Quality Management District on their Rule 1144. We believe Rule 

74.31, which closely follows SCAQMD Rule 1144, is an outstanding example of simultaneously protecting our 

environment while allowing manufacturers to continue to prosper. 

If you have any further questions, please call or write. We look forward to assisting VCAPCD in the implementation of 

74.31. 

Thomas J. Downs 

President 

www. wsdodgeoil. com
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.3332 Reagents for detection of specific novel influenza A viruses. ( a ) *Identification.* Reagents for detection of specific novel influenza A viruses are devices that are intended for use in a nucleic acid amplification test to directly detect specific virus RNA in human respiratory specimens or viral cultures. Detection of specific virus RNA aids in the diagnosis of influenza caused by specific novel influenza A viruses in patients with clinical risk of infection with these viruses, and also aids in the presumptive laboratory identification of specific novel influenza A viruses to provide epidemiological information on influenza. These reagents include primers, probes, and specific influenza A virus controls.
( b ) *Classification.* Class II (special controls). The special controls are: ( 1 ) FDA's guidance document entitled “Class II Special Controls Guidance Document: Reagents for Detection of Specific Novel Influenza A Viruses.” See § 866.1(e) for information on obtaining this document.
( 2 ) The distribution of these devices is limited to laboratories with experienced personnel who have training in standardized molecular testing procedures and expertise in viral diagnosis, and appropriate biosafety equipment and containment.
[71 FR 14379, Mar. 22, 2006]
Editorial Note on Part 886
Editorial Note: Nomenclature changes to part 886 appear at 73 FR 35341, June 23, 2008.

§ 886.1500 Headband mirror. ( a ) *Identification.* A headband mirror is a device intended to be strapped to the head of the user to reflect light for use in examination of the eye.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 886.9. The device is also exempt from the current good manufacturing practice requirements of the quality system regulation in part 820 of this chapter, with the exception of § 820.180, with respect to general requirements concerning records, and § 820.198, with respect to complaint files.
[52 FR 33355, Sept. 2, 1987, as amended at 53 FR 35605, Sept. 14, 1988; 66 FR 38811, July 25, 2001]
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7995 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7995

To amend the Internal Revenue Code of 1986 to include equitable tolling 
 for negligence or malfeasance by the Internal Revenue Service for the 
 period of limitation on filing for a credit or refund of overpayment.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             April 15, 2024

 Mr. Donalds introduced the following bill; which was referred to the 
                      Committee on Ways and Means

_______________________________________________________________________

                                 A BILL

 
To amend the Internal Revenue Code of 1986 to include equitable tolling 
 for negligence or malfeasance by the Internal Revenue Service for the 
 period of limitation on filing for a credit or refund of overpayment.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Protecting the American Taxpayer 
from IRS Mishandling Act of 2024''.

SEC. 2. EXTENDING THE RUNNING OF PERIODS OF LIMITATION FOR FILING FOR 
              CREDIT OR REFUND OF OVERPAYMENT TO INCLUDE MALFEASANCE OR 
              NEGLIGENCE BY THE INTERNAL REVENUE SERVICE.

    (a) In General.--Section 6511(h)(1) of the Internal Revenue Code of 
1986 is amended by striking ``during any period of such individual's 
life that such individual is financially disabled.'' and inserting 
``during--''
                    ``(A) any period of such individual's life that 
                such individual is financially disabled, or
                    ``(B) any period during which the taxpayer is 
                unable to file necessary documents or otherwise meet a 
                deadline in order to file a return as a result of 
                negligence (as defined in section 6662(c)) or 
                malfeasance of the Internal Revenue Service.''.
    (b) Conforming Amendment to Heading.--The heading for subsection 
(h) of section 6511 of such Code is amended by striking ``while 
taxpayer is unable to manage financial affairs due to disability'' and 
inserting ``while taxpayer is unable to file due to disability or 
negligence or malfeasance of Internal Revenue Service''.
    (c) Effective Date.--The amendments made by this section shall 
apply to returns filed after the date of the enactment of this Act.
                                 <all>
```
(logo)LNR

          Partners, LLC

 

 

ANNUAL STATEMENT OF COMPLIANCE

 

OF

 

LNR PARTNERS, LLC

 

 

The undersigned, Job Warshaw,being the President of LNR Partners, LLC (the “Special Servicer”), as special servicerunder the applicable Pooling and Servicing Agreement for the transactionslisted on Schedule I hereto, hereby certifies, subject to anylimitations listed on Schedule I hereto, as of the date hereof, onbehalf of the Special Servicer, solely in his capacity as an authorized officerof the Special Servicer and not in his individual capacity, as follows:

 

1.            A review ofthe activities performed by the Special Servicer during the period commencingon January 1, 2018 and ending on December 31, 2018 (or any other shorter periodset forth on Schedule I hereto) (the “'Reporting Period”), and of theSpecial Servicer’s performance under the Pooling and Servicing Agreement hasbeen made under my supervision; and

 

2.            To the bestof my knowledge, based on such review and using the applicable servicingcriteria under Item 1122 of Regulation AB, the Special Servicer has fulfilledall of its obligations under the applicable Pooling and Servicing Agreement inall material respects throughout the Reporting Period.

 

LNR PARTNERS, LLC,

a Florida limited liabilitycompany

 

 

By: /s/ Job Warshaw

Job Warshaw

President

 

 

Dated: February 19, 2019

 

 

1601 Washington Avenue • Suite 700 • Miami Beach,Florida 33139-3164

Telephone: (305) 695-5600 • Fax: (305) 695-5601

 

 

 

**Schedule I**

 

 

MSBAM 2015-C23

Morgan Stanley Bank of AmericaMerrill Lynch Trust 2015-C23, Commercial Mortgage Pass-Through Certificates,Series 2015-C23

 

Morgan Stanley Capital I Inc.

1221 Avenue of the Americas

New York NY 10020

James Y. Lee

 

Morgan Stanley Capital I Inc.

1585 Broadway

New York NY 10036

Stephen Holmes

 

Pentalpha Surveillance LLC

375 N. French Road, Suite 100

Amherst NY 14228

Don Simon

 

Pentalpha Surveillance LLC

Bass, Berry and Sims PLC

150 Third Avenue South, Suite2800

Nashville TN 37201

Jay H. Knight

 

Wells Fargo Bank, N.A.

9062 Old Annapolis Road

Columbia MD 21045

Group Notices

 

Wells Fargo Bank, N.A.

9062 Old Annapolis Road

MAC: R1204-010

Columbia MD 21045

Irene Kaplanis

 

Wilmington Trust, NationalAssociation

1100 North Market Street

Wilimington DE 19890

Dorri Costello

 

Wilmington Trust, NationalAssociation

1100 North Market Street

Wilmington DE 19890

Group
Exhibit 10.39
  th
    
    
    Paid cell phone reimbursement per company policy;
    
    Compensation: Annual salary of $200,000 ($8,333.34 semi-monthly, payable on
the 5th and 20th of each month);
    
    Incentive Plan: To be determined by the Compensation Committee of the Board of
Directors (short term and long term);
    
    Severance payable equal to four (4) months base salary upon termination for
any reason other than for an illegal act;
    
    Comprehensive health insurance package: Medical, Dental, Vision, Life,
Flexible Spending; Eligibility begins the first of the month following 30 days of
employment and deductions are pre-tax. Will be reimbursed for any COBRA payments made
before benefits are applicable at Ambassadors;
    
    401(k) Package: Includes up to $500 Matching Contribution by the company.
Employees are eligible to participate the first of the month after 90 days of employment.
Also a pre-tax deduction;
    
    Paid Time Off (PTO): The accrual rate for all eligible full-time employees
begins after 30 days of employment and the accrual rate is 11.34 hours per month, 136 hours
annually;
    
    Holiday Pay: Per company schedule for each year, 8 paid Holidays in 2009;
    
    Other benefits as described in the Companys Employee Handbook
    
    Paid parking




---



##### 



/s/ Mark T. Detillion

Mark T. Detillion
    
    2/28/2009

Date